| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
24 |
| Employees |
89 |
| Revenues (TTM) (Millions $) |
21 |
| Net Income (TTM) (Millions $) |
-74 |
| Cash Flow (TTM) (Millions $) |
-75 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Impel Pharmaceuticals Inc is a pharmaceutical company that focuses on developing innovative drug delivery systems for the treatment of various neurological disorders. They aim to deliver drugs directly to the brain for more targeted and effective treatment.
Impel Pharmaceuticals utilizes their proprietary Precision Olfactory Delivery, or POD, technology to administer therapies via the nasal cavity. This approach allows for rapid and efficient drug absorption, bypassing the blood-brain barrier for enhanced efficacy.
The company has a particular focus on developing treatments for migraine and other headaches, as well as other neurological conditions such as Parkinson's disease and schizophrenia. They have several drug candidates in their pipeline, and their technology has shown promising results in clinical trials.
Impel Pharmaceuticals strives to revolutionize neurological drug delivery and improve patient outcomes by providing more precise and convenient treatment options.
Company Address: 201 Elliott Avenue West Seattle 98119 WA
Company Phone Number: 568-1466 Stock Exchange / Ticker: NASDAQ IMPL
|
%
0.06%